Moderna
Search results
Our goal is clear: we want to provide better medicines for patients worldwide. Our toolbox includes a broad range of drug classes and platform technologies including mRNA-based therapies, cell therapies, small molecules as well as antibodies and other protein-based therapies.
- Our Senior Team
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023...
- Open Positions
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Vision & Mission
With decades of deep immunology expertise and experience in...
- Newsroom
First BioNTainer arrives in Rwanda - Sierk Poetting and...
- Therapeutic Areas
BioNTech initiated a clinical phase 1 trial for an...
- Manufacturing
As part of these plans, BioNTech is collaborating with the...
- Connect
At BioNTech, we believe that acting ethically and...
- MRNA
BioNTech has made great progress in developing cancer...
- Our Approach
We, at BioNTech, have a deep legacy of scientific...
- Our Board Members
He has guided BioNTech through a wide range of key business,...
- Our Senior Team
BioNTech US is a subsidiary of BioNTech SE, a leader in individualized neoantigen-targeted T cell therapies for cancer. Learn about its origins, vision, mission and NEO-STIM process for personalized and shared neoantigen products.
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
BioNTech is a global biotechnology company that develops immunotherapies for cancer, infectious diseases and other serious diseases. It was the first to create an approved mRNA vaccine for COVID-19 and has a diverse pipeline of product candidates based on mRNA and other technologies.
Aug 16, 2024 · Pfizer developed second-generation candidates with the goal of improving immunogenicity and potentially breadth of protection, including new tIRV formulations that matched updated recommendations by the World Health Organization (“WHO”) and the FDA’s Vaccines and Related Biological Products Advisory Committee (“VRBPAC”).
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted full approval by the FDA for individuals 16 years and older. It is also authorized for emergency use in individuals 12 years and older and for a third dose in certain immunocompromised people.
Comirnaty is the first COVID-19 vaccine to receive full FDA approval for individuals 16 years and older. It is a mRNA vaccine that prevents COVID-19 disease with 91% effectiveness and has the same formulation as the EUA vaccine.
People also ask
What does biontech stand for?
Who is biontech?
What is biontech – biopharmaceutical new technologies?
What makes biontech unique?
